| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
( Department of Experimental Pathology, Cancer Research Laboratories, The Hebrew University, Hadassah Medical School, Jerusalem, Israel)
Grafts of the mouse mammary carcinoma of the RIII strain (M.M.C.) can result in tumors in 100 per cent and kill 50100 per cent of rats pretreated at a suitable age with suitable doses of lyophilized mouse tumors or some normal mouse tissues of mice of the RIII strain.
The pretreatment of older animals, or of young animals with lower doses, results in a weaker effect, characterized by a lower percentage of takes and smaller, regressing tumors. There is a limit to the age and to the dose beyond which the pretreatment produces no effect.
The M.M.C. will grow in adult rats, provided the treatment was started early enough.
The M.M.C. and Sarcoma 37 will grow equally well in rats pretreated with lyophilized preparations of either of these tumors.
Pretreatment with tumor or normal tissue of species other than the mouse produces no effect.
The M.M.C. can grow progressively in rats pretreated with tissues of mice belonging to strains in which the M.M.C. does not grow.
Rats of two sublines of an inbred strain differed conspicuously in their response to treatment.
Received 4/10/56.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |